Twist Bioscience Co. (NASDAQ:TWST) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $48.22.

Several research firms have recently issued reports on TWST. The Goldman Sachs Group increased their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Barclays lowered their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Guggenheim initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Evercore ISI boosted their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd.

Twist Bioscience Stock Up 5.7 %

TWST stock opened at $45.00 on Friday. The stock has a market cap of $2.64 billion, a PE ratio of -13.39 and a beta of 1.80. The firm’s 50-day simple moving average is $50.65 and its 200 day simple moving average is $41.97. Twist Bioscience has a fifty-two week low of $14.42 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. Twist Bioscience’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.01) EPS. Equities analysts forecast that Twist Bioscience will post -3.13 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $47,120.94. Following the completion of the sale, the senior vice president now directly owns 90,593 shares of the company’s stock, valued at approximately $4,650,138.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Twist Bioscience news, SVP Paula Green sold 918 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $47,120.94. Following the completion of the sale, the senior vice president now directly owns 90,593 shares of the company’s stock, valued at $4,650,138.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,732 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total transaction of $85,578.12. Following the transaction, the chief executive officer now owns 505,846 shares in the company, valued at approximately $24,993,850.86. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,327 shares of company stock worth $978,760. 3.92% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in TWST. American International Group Inc. lifted its holdings in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after purchasing an additional 213 shares during the last quarter. Caprock Group LLC lifted its stake in shares of Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after buying an additional 220 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after buying an additional 308 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after buying an additional 312 shares during the last quarter. Finally, CWM LLC grew its stake in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.